ConvaTec (CTEC1N) AI Stock Analysis

ConvaTec

(BMV:CTEC1N)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring consumables modelConvaTec sells consumables that patients and healthcare providers must replenish regularly, creating recurring demand across ostomy, wound, continence and infusion care. This replacement-driven model can support durable revenue visibility and resilience across healthcare settings over the next several quarters.

Negative Factors

Higher leverageThe increase in debt relative to equity reduces financial flexibility and makes results more sensitive to earnings pressure or financing costs. Higher leverage may constrain capital allocation choices and leave less capacity to fund growth or absorb operational setbacks.

ConvaTec (CTEC1N) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 4.67B
Dividend Yield: 2.52%
Average Volume (3M): ―
Price to Earnings (P/E): 51.6
Beta (1Y): 0.07
Revenue Growth: -3.69%
EPS Growth: -46.66%
Country: Mexico
Employees: 10,910
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

ConvaTec Business Overview & Revenue Model

Company Description

ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, wher...

ConvaTec Earnings Call Summary

Earnings Call Date:Aug 03, 2026(Q2-2026)|% Change Since:-1.82%|Next Earnings Date:Feb 22, 2027

Earnings Call SentimentPositive

The call conveyed an upbeat, constructive tone: management confirmed they are on track for FY '26 targets (revenue growth, at least 23% operating margin, and continued double‑digit EPS growth), announced a USD 200m buyback and highlighted robust Infusion Care momentum, multiple product launches with strong clinical evidence (notably ConvaNiox) and clear CapEx to support long-term growth. Key challenges include the disappointing InnovaMatrix performance and impairment, softer wound care trading in parts of H1, H1 cash timing pressures, currency headwinds and a multi-year FDA remediation program. On balance, the positive execution on strategy, operational productivity, financing actions and high-confidence Infusion Care order visibility outweigh the near-term setbacks.

Positive Updates

Organic Revenue Growth (ex. InnovaMatrix)

Organic revenue growth excluding InnovaMatrix was 5% in H1 2026, in line with expectations and demonstrating broad-based growth across the business.

Negative Updates

InnovaMatrix Sales Collapse and Impairment

InnovaMatrix sales fell by USD 37m YoY to USD 2.5m in H1; company now forecasts full-year 2026 revenue of USD 5m–10m for InnovaMatrix (H1 headwind ~3% to group revenue, FY headwind ~2.5%, H2 headwind ~2%). A non-cash impairment of USD 69m was recorded. Management expects InnovaMatrix to be small going forward and breakeven at ~USD 10m of revenue.

Company Guidance

Convatec reiterated FY‑26 and medium‑term guidance: organic revenue growth for H2 narrowed to 6–8% (with group mid‑term growth target 6–8% p.a. from 2027), Infusion Care expected to be double‑digit in H2 (high‑single‑digit for FY‑26), and operating margin at least 23% for FY‑26 (inclusive of ~80bps InnovaMatrix and ~40bps FX headwinds) with H2 around mid‑20s (~25%) and mid‑20s thereafter; management is “on track” for double‑digit EPS growth (H1 EPS +6%) and targets double‑digit EPS annually from 2027, ~100% free‑cash‑flow‑to‑equity conversion for the year, a $200m share buyback to complete by year‑end, year‑end leverage ~2x EBITDA (H1 2.3x), continued growth CapEx (c.$90m increase focused on Infusion Care) plus operational CapEx ~2.5% of revenue, and InnovaMatrix now expected $5–10m for FY‑26 (H1 sales $2.5m, -$37m y/y) with a $69m non‑cash impairment.

ConvaTec Peers Comparison

Overall Rating

Financial Indicators

MX:CTEC1N against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:CTEC1N and its peers over the selected period
Show on chart	Ticker	Company Name	Price	Change	% Change
	MX:CTEC1N	ConvaTec Group plc	58.67	-1.09	-1.82%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

ConvaTec AI Stock Analysis